BIOS

Bringing Decades of Successful Biotech Company Growth, Financing, IPO and M&A Expertise ReAlta Life Sciences Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Jonathan Rigby as a member of the ReAlta Life Sciences Board of Directors. Howard Berman, Ph.D., executive chairman, stated: "Jonathan brings a rare combination of entrepreneurial drive, disciplined company-building, and proven capital-markets execution. He has repeatedly demonstrated the ability to raise significant capital,

SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)

SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)

SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)

SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)

15-12G - BioPlus Acquisition Corp. (0001856653) (Filer)

25-NSE - BioPlus Acquisition Corp. (0001856653) (Subject)

RW - BioPlus Acquisition Corp. (0001856653) (Filer)

Avertix Medical, Inc. ("Avertix" or the "Company"), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, and BIOS Acquisition Corporation (dba BioPlus Acquisition Corp.) ("BIOS") (NASDAQ:BIOS), a special purpose acquisition company, announced today that the two companies have mutually agreed to terminate their proposed business combination.

8-K - BioPlus Acquisition Corp. (0001856653) (Filer)

New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. ("BIOS" or the "Company") (NASDAQ:BIOS) announced today that (i) BIOS, Avertix Medical, Inc. and certain other parties have mutually agreed to terminate their previously announced business combination agreement and plan of reorganization (the "Business Combination Agreement"), effective as of October 4, 2023 and (ii) it intends to liquidate as soon as practicable after October 4, 2023 and to return funds to holders of its Class A ordinary shares that were included in the units issued in the Company's initial public offering ("Public Shares"). The Business Combination Agreement was dated as of May 2, 2023. The pa

EATONTOWN, N.J. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. ("Avertix" or the "Company"), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, and BIOS Acquisition Corporation (dba BioPlus Acquisition Corp.) ("BIOS") (NASDAQ:BIOS), a special purpose acquisition company, announced today that the two companies have mutually agreed to terminate their proposed business combination. "While we were enthusiastic about the potential business combination with BIOS, we mutually agreed that the current market conditions are not co

425 - BioPlus Acquisition Corp. (0001856653) (Subject)

Bioservo signs a Sales Agent agreement with Trivet Medical LLC for sales of Carbonhand to Hospitals, Clinics, and Medical Centers within the Veterans Health Administration and Department of Defense in the US. With the first Sales Agent in place, the grip-strengthening device Carbonhand is available for all US Veterans suffering from impaired hand function. KISTA, Sweden, Aug. 29, 2023 /PRNewswire/ -- Trivet Medical LLC is a specialized strategic sales and distribution LLC, highly focused on commercializing disruptive, best-in-class med-tech devices and technologies. Founded by Charles Coyle, Trivet Medical's mission is to develop underrepresented and underserved healthcare conditions through

425 - BioPlus Acquisition Corp. (0001856653) (Subject)

The Avertix Guardian™ System, the first and only FDA approved implantable heart attack warning system, now available at the Heart & Rhythm Institute of Trinity, extending their commitment to redefining cardiac care in the Tampa, FL area Dr. Luis R. Annoni-Suau, MD, FACC and Dr. Carlos J. Bayron successfully performed the first two Guardian implants at the Heart and Rhythm Institute of Trinity

The Avertix Guardian™ System, the first and only FDA approved implantable heart attack warning system, now available at the Heart & Rhythm Institute of Trinity, extending their commitment to redefining cardiac care in the Tampa, FL area Dr. Luis R. Annoni-Suau, MD, FACC and Dr. Carlos J. Bayron successfully performed the first two Guardian implants at the Heart and Rhythm Institute of Trinity EATONTOWN, N.J. and TRINITY, Fla., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. ("Avertix" or the "Company"), a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, and the Heart & Rhythm Inst

Bioservo signs a wholesale distributor agreement with Veterans Healthcare Supply Solutions for sales of Carbonhand in the US. The initial intent of the agreement is to make Carbonhand available for Veterans Administration Facilities (VA) and Department of Defense Healthcare Facilities (DoD). The agreement can also be expanded to include other customer segments.  STOCKHOLM, Aug. 16, 2023 /PRNewswire/ -- Veterans Healthcare Supply Solutions (VHSS) has over 30 years of healthcare distribution management experience and represents leading manufacturers to federal government agencies. Established in 2010, VHSS has been a veteran-driven medical product distribution company and has taken the collect

10-Q - BioPlus Acquisition Corp. (0001856653) (Filer)

S-4/A - BioPlus Acquisition Corp. (0001856653) (Filer)

425 - BioPlus Acquisition Corp. (0001856653) (Subject)

Recently served as Boston Scientific Executive Vice President and Global Chief Medical Officer Professor Meredith brings to Avertix over 35 years of cardiology experience and commitment to advancing cardiac care EATONTOWN, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. ("Avertix" or the "Company"), formerly known as Angel Medical Systems, Inc., a healthcare technology company commercializing the first and only FDA-approved heart attack warning system to improve long-term management and outcomes of high-risk coronary disease in patients, announced today that Professor Ian Meredith AM, has agreed to join the Company's Board of Directors following the closing of the Company's

S-4/A - BioPlus Acquisition Corp. (0001856653) (Filer)

425 - BioPlus Acquisition Corp. (0001856653) (Subject)

8-K - BioPlus Acquisition Corp. (0001856653) (Filer)